Comparing oral and intratympanic corticosteroids for sudden hearing loss
Official title: Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
Run by Dr. Lutfi Kirdar Kartal Training and Research Hospital · NCT06968507 · Data updated 2026-11-12
This study is testing whether taking corticosteroids by mouth or getting them through an injection in the ear works better for people with sudden hearing loss.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 214 (estimated) |
| Sponsor | Dr. Lutfi Kirdar Kartal Training and Research Hospital Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Istanbul, Kartal) |
| Status | Recruiting |
| Started | December 25, 2024 |
| Main results expected | September 10, 2028 |
| Study ends | September 10, 2028 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT06968507 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with unilateral sudden sensorineural hearing loss that developed within the last 72 hours.
✕Probably not a fit
Patients with a history of hearing-related surgery, chronic ear diseases, or other specified exclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to determine the effectiveness of two corticosteroid treatment methods for patients with sudden sensorineural hearing loss: oral methylprednisolone and intratympanic dexamethasone. Participants will be divided into two groups, with one receiving oral medication and the other receiving intratympanic injections over a specified treatment period. Follow-up visits will occur at regular intervals to assess hearing recovery and overall outcomes. The study seeks to provide clarity on which treatment option yields better results for patients experiencing this condition.
Why it matters
Potential benefit: If successful, this study could identify a more effective treatment option for sudden sensorineural hearing loss, potentially improving patient outcomes.
How similar studies have gone: Previous studies have explored corticosteroid treatments for hearing loss, but this specific comparison of oral versus intratympanic administration is less common, making it a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age and older * Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less * Affected side PTA (500-100-2000-4000hz) should be over 50dB * Affected side should be at least 30dB lower than healthy side in 3 frequencies * Hearing should be symmetrical according to patient's statement before sensorineural hearing loss * If used, steroid use should be less than 10 days * Cerebellar and vestibular examination should be normal Exclusion Criteria: * Having a history of hearing-related surgery other than a ventilation tube * Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or cholesteatoma, otosclerosis * Being under 18 or over 80 * Having a history of physical-barotrauma * Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss * Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with atherosclerotic disease, serious psychiatric patients, those receiving chemotherapy, radiotherapy or immunosuppressant treatment, pancreatitis patients, HIV, hepatitis C and B patients, those with chronic renal failure, substance abusers, those with active herpetic lesions, severe osteoporosis patients, those with hearing loss within 4 weeks after general anesthesia, those with a history of head and neck cancer.
Where it's running
-
Dr Lütfi Kırdar City Hospital
Istanbul, Kartal, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Koray Islek
- Email: islekkoray@gmail.com
- Phone: +905380457016
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cohort of patients with sudden sensorineural hearing loss
This study is tracking patients with sudden hearing loss to see how well different treatments help them recover over time.
-
Acupuncture plus steroids for sudden sensorineural hearing loss
This trial will test whether adding acupuncture to steroid treatment helps adults with sudden sensorineural hearing loss recover hearing and reduce symptoms like tinnitus and dizziness.
-
Biomarkers in Congenital Hearing Loss: Alpha-Tectorin, IL-10, and Thiol-Disulfide Balance in Children
This observational study tests whether levels of alpha-tectorin, IL-10, and thiol-disulfide balance differ in children with congenital sensorineural hearing loss (with cochlear implants or hearing aids) compared with healthy children.
-
Anatomy-based fitting for single-sided deaf CI users
This study tests whether anatomy-based fitting changes how well adults with single-sided deafness use a cochlear implant to understand speech in noise and to enjoy music.
-
Long-term outcomes of MED-EL SONATA 2 Cochlear Implants in real life
This study looks at long-term results from people who received a SONATA 2 cochlear implant to see how well it works in everyday life.
-
Anatomy-Based Fitting for People with a Cochlear Implant and Hearing Aid
This study tests whether an anatomy-based frequency distribution works better than the default one for adults with a cochlear implant and a contralateral hearing aid.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.